Novel fibrinogen receptor antagonists of the formula: X--Y--Z--Aryl--A--B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.
OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS
申请人:Galderma Research & Development
公开号:EP2342194A1
公开(公告)日:2011-07-13
US5648368A
申请人:——
公开号:US5648368A
公开(公告)日:1997-07-15
[EN] FIBRINOGEN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DU FIBRINOGENE
申请人:——
公开号:WO1994012181A1
公开(公告)日:1994-06-09
[EN] Novel fibrinogen receptor antagonists of the formula: X-Y-Z-Aryl-A-B are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation. [FR] L'invention concerne des nouveaux antagonistes des récepteurs du fibrinogène représentés par la formule: X-Y-Z-Aryl-A-B Les composés selon l'invention agissent en tant qu'antagonistes des récepteurs du fibrinogène, inhibent l'agrégation plaquettaire et sont utilisés pour moduler la formation de thrombus.
[EN] SMALL MOLECULE VE-PTP INHIBITORS<br/>[FR] INHIBITEURS DE VE-PTP À PETITES MOLÉCULES
申请人:RIPKA AMY
公开号:WO2021257754A1
公开(公告)日:2021-12-23
The present disclosure relates to compounds capable of inhibiting vascular endothelial protein tyrosine phosphatase (VE-PTP). These compounds are also capable of activating Tie2 receptor-mediated signaling. The present disclosure also relates to pharmaceutically acceptable salts of said compounds, to pharmaceutical compositions comprising such compounds and/or pharmaceutically acceptable salts thereof, and to the use of such compounds, pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions comprising the same in treating diseases and/or conditions mediated by VE-PTP signaling, such as those mediated by Angiopoietm/Tie2 signaling.